NGS Combined With RNAseq on Tumor Immune Escape in NSCLC

Study on the Effect of NGS Combined With RNAseq on Tumor Immune Escape in Advanced Non-small Cell Lung Cancer EGFR and ALK Mutant Negative Patients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03764917

Enrollment

100

Registered

2018-12-05

Start date

2018-12-01

Completion date

2021-12-31

Last updated

2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small Cell Lung Cancer

Keywords

NGS, RNAseq

Brief summary

Study on the tumor immune escape in advanced non-small cell lung cancer patients with EGFR and ALK mutant negative by NGS combined with RNAseq

Detailed description

Study on the tumor immune escape in advanced non-small cell lung cancer patients with EGFR and ALK mutant negative by NGS combined with RNAseq. Detecting non-small cell lung cancer patient NGS and RNAseq data before first-line chemotherapy, after two cycles chemotherapy and after disease progression.

Interventions

OTHERTime

Different detecting time

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

Non-small cell lung cancer patient First-line chemotherapy with platinum-based chemotherapy

Exclusion criteria

EGFR mutant positive Alk mutant positive

Design outcomes

Primary

Measure	Time frame	Description
numbers of immune cells	24 months	detecting numbers of immune cells before first-line chemotherapy, after two cycles chemotherapy and after disease progression

Secondary

Measure	Time frame	Description
numbers of tumor mutations	24 months	detecting numbers of tumor mutations before first-line chemotherapy, after two cycles chemotherapy and after disease progression

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 16, 2026